Thieler Law Corp advises investors with losses exceeding $100,000 of the June 19, 2018 lead plaintiff deadline in a class action lawsuit filed against Myriad Genetics Inc (NASDAQ: MYGN) (“Myriad” or “the Company”). The suit is pending in the U.S. District Court for the District of Utah and investors, who purchased Myriad Genetics Inc securities between August 13, 2014, and March 12, 2018, have until June 19, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Myriad Genetics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and as a result, Myriad’s public statements were materially false and misleading at all relevant times.

On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services in connection with an investigation into possible false Medicare and Medicaid payment claims. The subpoena purportedly requested documents “relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.”

Following this news, NASDAQ: MYGN fell $4.01 per share, or 12.1%, to close at $29.01 per share on March 13, 2018, thereby injuring investors.

If you were negatively impacted by your investment in Myriad Genetics Inc securities between August 13, 2014, and March 12, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185